PEGylation of Interferon-β-1a

@article{Kieseier2012PEGylationOI,
  title={PEGylation of Interferon-$\beta$-1a},
  author={Bernd C. Kieseier and Peter A. Calabresi},
  journal={CNS Drugs},
  year={2012},
  volume={26},
  pages={205-214}
}
Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are covalently attached to a biological or small-molecule drug, effectively transforming it into a therapy with improved pharmacokinetic and pharmacodynamic… 
An update on the evidence base for peginterferon β1a in the treatment of relapsing–remitting multiple sclerosis
TLDR
Peginterferon β1a administered every 2 weeks resulted in a more robust treatment effect on ARR, sustained disability progression and magnetic resonance imaging endpoints than peginterferonβ1a every 4 weeks, and an adverse-effect profile similar to other interferon α formulations coupled with the advantage of a significant reduction in the number of injections, could lead to improved long-term adherence to peginerferonbeta.
Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial
TLDR
The treatment effect of peginterferon beta1a in patients with relapsing–remitting MS is not expected to be attenuated by immunogenicity, although these analyses were limited by the low incidence of treatment-emergent antibodies.
COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
TLDR
Numerically lower frequencies and incidence rates of ISRs, headache, myalgia and chills were observed with s.c. peginterferon beta‐1a three times a week over 2 weeks, and a lower frequency of AEs.
Peginterferon beta-1a for the treatment of relapsing multiple sclerosis: A case series.
  • B. Hendin
  • Medicine
    Multiple sclerosis and related disorders
  • 2018
TLDR
With appropriate patient education and expectation setting regarding potential flu-like symptoms and injection-site reactions, peginterferon beta-1a may be a beneficial alternative for patients who prefer less frequent injections.
Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
TLDR
The results do not warrant peginterferon beta‐1a dose adjustment in subjects with renal impairment and neopterin baseline, peak concentration, and AUC increased as renal function decreased.
Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
TLDR
Subcutaneous peginterferon beta-1a every 2 weeks extends the treatment options currently available for adults with RRMS, with the dosing regimen imparting potential compliance advantages over non-PEGylated interferon Beta formulations that require more frequent administration.
Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
TLDR
An overview of the role of IFN in the treatment of MS is provided and the available evidence for pegylated IFN therapy in MS is evaluated.
Glycoengineering of Interferon-β 1a Improves Its Biophysical and Pharmacokinetic Properties
TLDR
Hyperglycosylated rhIFn-β could be a biobetter version of rhIFN-β 1a with a potential for use as a drug against multiple sclerosis.
Peginterferon beta-1a in relapsing–remitting multiple sclerosis: a guide to its use in the EU
TLDR
Peginterferon beta-1a (Plegridy™) extends the options currently available to treat adults with relapsing–remitting multiple sclerosis (RRMS) and provides potential compliance advantages over non-pegylated interferonbeta formulations that require more frequent administration.
Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?
TLDR
The shortcomings of the parent drugs are addressed, the pros and cons of the second-generation therapies are presented, and upcoming developments in the field of immunotherapy for multiple sclerosis are summarized.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 71 REFERENCES
Pegylated IFNs for chronic hepatitis C: an update
TLDR
Comparative trials have been initiated that will provide insight into relative importance of pharmacokinetics, bioactivity and dosing regimen, and this may translate into -differences in clinical efficacy.
Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients
TLDR
With its more convenient dosing regimen, pegfilgrastim has the potential to improve quality of life and compliance in patients, and to be more cost effective.
Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients
TLDR
Clinical trials indicate a doubling of sustained virological response rates for regimens utilising pegIFNalpha-2b, compared with standard IFN alpha-2B, and the combination of pegIFn alpha- 2b and ribavirin further increases the sustained virology response rates to > 50% for suitable patients.
N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
TLDR
Since unmodified IFN-beta is used for the treatment of multiple sclerosis and hepatitis C virus infection, a PEGylated form of the protein such as 20 kDa mPEG-O-2-methylpropionaldehyde-modified IFn-beta-1a may serve as a useful adjunct for the Treatment of these diseases.
Pegylated Interferons for the Treatment of Chronic Hepatitis C
TLDR
Peginterferon plus ribavirin, as the standard of care for patients with chronic hepatitis C, may in the future form the basis of improved treatment regimens that include new, targeted anti-HCV agents to increase SVR rates even further.
Pegylation: a novel process for modifying pharmacokinetics.
TLDR
Pegylation may be an effective method of delivering therapeutic proteins and modifying their pharmacokinetic properties, in turn modifying pharmacodynamics, via a mechanism dependent on altered binding properties of the native protein, and may result in more constant and sustained plasma concentrations.
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.
  • D. Baker, R. Pepinsky, +15 authors G. Davar
  • Medicine
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • 2010
TLDR
The development of a PEGylated form of interferon beta-1a that is currently being tested in a multicenter, randomized, double-blind, parallel-group, placebo-controlled study in relapsing multiple sclerosis patients, with the aim of determining the safety and efficacy of 125 microg administered via the subcutaneous route every 2 or 4 weeks.
Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a
TLDR
The chemistry, clinical pharmacology, pharmacokinetics, pharmacodynamics, and clinical studies with 40 kDa pegylated interferon are examined to illustrate the general principles of pegylation.
PEG conjugates in clinical development or use as anticancer agents: an overview.
TLDR
PEGylation proved to be effective in shielding sensitive sites at the protein surface, such as antigenic epitopes and enzymatic degradable sequences, as well as in prolonging the drug half-life by decreasing the kidney clearance.
Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.
TLDR
The role of pegylated interferons in the setting of advanced metastatic melanoma will need further investigation in clinical trials, potentially in combination with targeted or cytotoxic agents with regard to synergistic antiangiogenic and cytotoxicity effects.
...
1
2
3
4
5
...